Press Releases

Email Alerts

Apr 2, 2018

Biostage Reports 2017 Financial Results

- Fourth Quarter Headcount Reduction and Private Placement Extend Operational Runway

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
- Photos 1
Mar 29, 2018

Biostage Names Distinguished Children's Hospital Executive James Shmerling to its Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it...
- Photos 1
Mar 29, 2018

Biostage awarded SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for esophageal atresia in pediatric patients

- Potential to provide up to $1.7 million of nondilutive funds to support pre-clinical testing of Company's pediatric esophageal implant product candidate

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
Mar 13, 2018

Biostage Preclinical Study Results Published in New Report

Large-animal study results published in Nature Scientific Reports show successful esophageal regeneration

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the publication of...
Feb 20, 2018

Biostage Closes $1 Million Private Placement

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the previously disclosed...
Feb 12, 2018

Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the appointment of Charles...
- Photos 1
Feb 7, 2018

Biostage, Inc. Names Jason Chen Chairman of its Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it...
- Photos 1
Feb 6, 2018

Biostage to Host Conference Call to Provide Business Update

- Conference Call with Live Audio Webcast on Tuesday, February 13th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that on...
Jan 31, 2018

Biostage Appoints to its Scientific Advisory Board Christine Finck, MD, Executive Vice President, Surgeon-in-Chief at Connecticut Children's Medical Center

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced the...
Jan 3, 2018

Biostage Closes $4.2 Million Private Placement

- Investors strongly back technology, advancement to the clinic in U.S. Market-

Biostage, Inc. (OTCQB: BSTG/BSTGD), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...

Show per page